{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:43:21Z","timestamp":1790675001014,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.ctro.2019.04.020","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T20:23:45Z","timestamp":1556223825000},"page":"128-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["The role of biological dose-escalation for pancreatic cancer"],"prefix":"10.1016","volume":"18","author":[{"given":"Anna M.E.","family":"Bruynzeel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8740-2517","authenticated-orcid":false,"given":"Frank J.","family":"Lagerwaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"69","key":"10.1016\/j.ctro.2019.04.020_b0005","first-page":"7","article-title":"Cancer statistics, Cancer statistics, 2019","volume":"2019","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ctro.2019.04.020_b0010","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without Erlotinib: The LAP07 Randomized Clinical Trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ctro.2019.04.020_b0015","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2019.04.020_b0020","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/jso.25233","article-title":"FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study","volume":"118","author":"Suker","year":"2018","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ctro.2019.04.020_b0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1245\/s10434-018-6931-6","article-title":"How Does chemoradiotherapy following induction FOLFIRINOX improve the results in resected borderline or locally advanced pancreatic adenocarcinoma? An AGEO-FRENCH multicentric cohort","volume":"26","author":"Pietrasz","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctro.2019.04.020_b0030","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","article-title":"Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation","volume":"94","author":"Krishnan","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2019.04.020_b0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/COC.0000000000000518","article-title":"Pattern of marginal local failure in a phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer","volume":"42","author":"Kharofa","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctro.2019.04.020_b0040","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijrobp.2016.10.030","article-title":"Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials","volume":"97","author":"Petrelli","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2019.04.020_b0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/COC.0000000000000472","article-title":"Dose escalation in stereotactic body radiation therapy for pancreatic cancer: a meta-analysis","volume":"42","author":"Zaorsky","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctro.2019.04.020_b0050","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","article-title":"Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen","volume":"126","author":"Henke","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2019.04.020_b0055","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/j.prro.2018.08.010","article-title":"Dosimetric benefits and practical pitfalls of daily online adaptive MRI-guided stereotactic radiation therapy for pancreatic cancer","volume":"9","author":"El-Bared","year":"2019","journal-title":"Pract Radiat Oncol"},{"issue":"Suppl.","key":"10.1016\/j.ctro.2019.04.020_b0060","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/j.ijrobp.2017.06.293","article-title":"Stereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors","volume":"99","author":"Bruynzeel","year":"2017","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2019.04.020_b0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.radonc.2018.08.009","article-title":"Retrospective evaluation of decision-making for pancreatic stereotactic MR-guided adaptive radiotherapy","volume":"129","author":"Tyran","year":"2018","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2019.04.020_b0070","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.radonc.2017.07.028","article-title":"Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer","volume":"125","author":"Bohoudi","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2019.04.020_b0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.radonc.2018.11.019","article-title":"Identification of patients with locally advanced pancreatic cancer benefitting from plan adaptation in MR-guided radiation therapy","volume":"132","author":"Bohoudi","year":"2019","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2019.04.020_b0080","article-title":"Combined inter- and intrafractional plan adaptation using fraction partitioning in magnetic resonance-guided radiotherapy delivery","volume":"10","author":"Lagerwaard","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.ctro.2019.04.020_b0085","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer","author":"Rudra","year":"2019","journal-title":"Cancer Med"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630819300783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630819300783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:06:10Z","timestamp":1762502770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630819300783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":17,"alternative-id":["S2405630819300783"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2019.04.020","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of biological dose-escalation for pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2019.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}]}}